NCT01751984View on ClinicalTrials.gov

A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 4, 2012

Primary Completion Date

May 1, 2013

Study Completion Date

May 1, 2013

Conditions
Hypercholesterolemia
Interventions
DRUG

ETC-1002

Weeks 1-2, 60 milligrams per day (mg/day); Weeks 3-4, 120 mg/day; Weeks 5-6, 180 mg/day; Weeks 7-8, 240 mg/day

DRUG

Placebo

Placebo once daily for 8 weeks

Trial Locations (5)

27609

Raleigh

28401

Wilmington

37912

Knoxville

46260

Indianapolis

06102

Hartford

Sponsors
All Listed Sponsors
lead

Esperion Therapeutics, Inc.

INDUSTRY